Closed tender

NHS National Generic Pharmaceuticals Wave 13

Details

Buyer: NHS England
Value: GBP 1,637,875,080
Topic: Pharmaceutical products
Published: 21 June 2021
Submission: 26 July 2021
Source: uk:find_a_tender

Tender description

Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months) Lot 1: Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus) Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Lot 3 - CM/PHG/17/5532/02 Hospital Only Products Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 1: Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus) Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Lot 3 - CM/PHG/17/5532/02 Hospital Only Products Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Transition (Everolimus) CESW: 1 March 2022 – 30 September 2023 (19 months) LSNE: 1 March 2022 – 31 January 2023 (11 months) NWLN: 1 March 2022 – 31 January 2023 (11 months) Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months) Hospital Only Products CESW: 1 February 2022 – 30 September 2023 (20 months) LSNE: 1 February 2022 – 31 May 2024 (28 months) NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Timeline

Completed: Tender published21 June 2021
Current notice
Completed: Submission date26 July 2021

About the buyer

NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

Relevant CPV codes

33600000 · Pharmaceutical products

Decision makers

Connect with the people behind this procurement.

Job title	Phone number	Work email
Head of Procurement	+44 •••• ••••••	••••••••@nhs-england.gov
Commercial Director	+44 •••• ••••••	••••••••@nhs-england.gov
Procurement Manager	+44 •••• ••••••	••••••••@nhs-england.gov
Category Lead	+44 •••• ••••••	••••••••@nhs-england.gov
Senior Buyer	+44 •••• ••••••	••••••••@nhs-england.gov
Contracts Manager	+44 •••• ••••••	••••••••@nhs-england.gov